J&J Rybrevant/Lazcluze study shows superiority over lazertinib for NSCLC

Johnson & Johnson (JNJ) announced longer follow-up data from the landmark Phase 3 MARIPOSA study which showed first-line treatment with RYBREVANT or amivantamab-vmjw combined with LAZCLUZE or lazertinib provided consistent benefit across long-term outcomes compared to osimertinib monotherapy in adult patients with advanced non-small cell lung cancer NSCLC with epidermal growth factor receptor EGFR exon 19 deletions or L858R substitution mutations. The data show a strong and improving overall survival OS trend favoring RYBREVANT plus LAZCLUZE at approximately three years of follow-up. These results were presented in a late-breaking oral presentation at the International Association for the Study of Lung Cancer IASLC 2024 World Conference on Lung Cancer WCLC…”By combining the multi-targeted mechanism of RYBREVANT with LAZCLUZE, a central nervous system-penetrant third-generation tyrosine kinase inhibitor, we are advancing a chemotherapy-free regimen for the first-line treatment of patients with EGFR-mutant NSCLC. This approach blocks EGFR and MET pathways and leverages the immune system, offering patients an opportunity for prolonged benefits,” said Shirish M. Gadgeel, M.D., Chief of Division of Hematology and Oncology, Associate Director at Henry Ford Cancer Institute and presenting author. “Even more encouraging is the marked improvement in the hazard ratio and the ongoing separation of survival curves, showing an eight percent improvement at three years for RYBREVANT plus LAZCLUZE compared to osimertinib (AZN). This supports the long-term benefit of the combination as a first-line treatment option in this setting.”